altRX vs GoodRx
altRX and GoodRx both sell tirzepatide; this is how their prices, coverage and records differ.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
If you are choosing between altRX and GoodRx, price alone will not settle it. Both prescribe tirzepatide, so moving from one to the other would not change your drug. GoodRx leads our six-part score, 6.9 to 6.7. One of the two has an FDA warning letter on record, covered below.
altRX vs GoodRx price
altRX and GoodRx start at the same figure, $149 a month, so the entry price does not separate them. Look at what each price covers and at the per-drug prices below.
Drug by drug: Tirzepatide is cheaper at altRX ($249 a month vs $299 a month).
Medications and formats
Both sell tirzepatide; only altRX lists semaglutide; only GoodRx lists orforglipron.
On format, altRX prices compounded injections and brand-name pens, while GoodRx prices brand-name pens.
Where each one treats patients
altRX does not publish where it ships, and GoodRx lists 50 states.
Pricing
altRX
GoodRx
What each price covers
altRX's price also covers the clinician visit, the medication itself and shipping, which GoodRx does not claim.
altRX is silent on lab work and coaching.
GoodRx does not say what its price includes.
That matters most for the drug: unless GoodRx confirms otherwise, budget for medication on top of its listed price.
altRX
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
GoodRx
Inclusions not disclosed.
Where each one scores higher
Overall, GoodRx scores 6.9 and altRX 6.7 out of 10.
altRX is stronger on user experience (8.0 vs 5.0) and support (7.0 vs 5.0).
GoodRx is stronger on trust & safety (6.0 vs 3.5) and accessibility (10.0 vs 5.0).
Value and effectiveness are within half a point.
altRX
6.7/10
GoodRx
6.9/10
Value25%
Effectiveness25%
User Experience15%
Trust & Safety15%
Accessibility10%
Support10%
FDA warning letters
The FDA sent altRX a warning letter dated June 8, 2026 (letter 728236), and it is still open.
GoodRx has no FDA warning letter on record with us.
Features & Coverage
| Feature | altRX | GoodRx |
|---|---|---|
| Starting Price | $149/mo | $149/mo |
| Features | ✓8 features | 6 features |
| States Available | Not disclosed | 50 |
| Compounded | ✓ Yes | — |
| Brand Name | ✓ Yes | ✓ Yes |
| FSA/HSA Accepted | — | — |
| FDA Warning Letters | 1 letter | ✓None |
About altRX
Compounded plans open at $149 for semaglutide and $249 for tirzepatide. Branded medication runs $1,149-$1,579, a figure that already contains the consult and the shipping. Every one of the four FDA-approved brands is stocked, Mounjaro, Ozempic, Wegovy and Zepbound, which no other entry in our directory matches. altRX works in both modalities, holds LegitScript certification, and prints the FDA compounded-medication disclaimer.
Read our full altRX review →About GoodRx
GoodRx (NASDAQ: GDRX) is the largest US prescription savings platform. It publishes self-pay discount pricing on brand-name GLP-1 medications, with Foundayo (orforglipron) starting at $149/month and the Zepbound KwikPen (tirzepatide) starting at $299/month, redeemable at 70,000+ pharmacies nationwide. It also operates GoodRx Care, a telehealth arm that prescribes GLP-1s with online visits starting at $39.
Read our full GoodRx review →Pros & Cons
altRX
What we like
- Tirzepatide costs $1249 a month, close to the $1249 median for brand-name tirzepatide across the sellers we compare
- Shows its price before the medical questionnaire, so you can compare it without handing over health information
- The monthly price includes the medication, clinician visits and shipping
Watch-outs
- Semaglutide costs $1149 a month, 16% above the $990 median for brand-name semaglutide across the sellers we compare
- Confirm it serves your state before you start the intake
- Ask which pharmacy fills the prescription before you pay, so you can check its license
- The FDA has issued altRX a warning letter. Read what it alleges: a letter flags a problem but does not by itself rule a seller out
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
GoodRx
What we like
- Orforglipron costs $149 a month, close to the $149 median for brand-name orforglipron across the sellers we compare
- Tirzepatide costs $299 a month, 76% below the $1249 median for brand-name tirzepatide across the sellers we compare
- Serves all 50 states
- We found no FDA warning letters issued to GoodRx
Watch-outs
- Ask which pharmacy fills the prescription before you pay, so you can check its license
Our Verdict
GoodRx wins this one, 6.9 to 6.7, above all for oral orforglipron alongside the injectables. altRX fits better if semaglutide from $1149/month is your priority.
Choose altRX if…
You want semaglutide from $1149/month and an opening price near $149 a month.
Choose GoodRx if…
You want oral orforglipron alongside the injectables and an opening price near $149 a month.
Ready to start? GLP-1 providers we have vetted
Telehealth providers, vetted by us, prescribing GLP-1 online.
Vetted by our editors · no insurance required
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
He & She MD
Starting below a standard dose, with microdose tiers
From $99/mo
Get started →Wellorithm
Compounded semaglutide at $247/month
From $247/mo
Get started →Willow
Seeing what it charges before you answer any medical questions
From $299/mo
Get started →altRX vs GoodRx: FAQ
Close alternatives to altRX and GoodRx
- altRX vs Gala
- altRX vs Sprout Health
- altRX vs Aquivia Health
- altRX vs Vytora Health
- GoodRx vs Found
- GoodRx vs Kin Meds
Or see the full category ranking.
Novo Nordisk A/S owns the Wegovy®, Ozempic® and Rybelsus® marks; Eli Lilly and Company owns Mounjaro® and Zepbound®. Every other product name and mark on this page belongs to whoever owns it. No pharmaceutical manufacturer is affiliated with GLP Watchdog. See trademark disclaimer.